The role of YKL-40 in Alzheimer’s disease pathology and drug targeting
PeerJ · 08.06.2026 · 14 · e21361
DOI: 10.7717/peerj.21361 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PeerJ, online erschienen am 08.06.2026. Verfasst von Yaru Sha und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Shandong Second Medical University, Weifang, Shandong, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Chitinase-3-Like Protein 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Shandong Provincial Natural Science Foundation, Shandong Provincial Medical and Health Science and Technology Development Program.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques, hyperphosphorylated tau tangles, and significant neuronal loss. Recent studies have implicated YKL-40, a glycoprotein commonly associated with inflammation and neural apoptosis, in the pathogenesis of AD.
Methods
We conducted extensive searches across major scientific databases, including PubMed, Web of Science, and Embase. We selected peer-reviewed articles, review articles, and clinical studies focusing on YKL-40 in AD.
Results
This review comprehensively analyses the multifaceted role of YKL-40 in AD, covering its cellular localization, biomarker associations, and pathological mechanisms. We also summarize the mechanistic pathways by which YKL-40 contributes to disease progression, highlighting its role in neuroinflammation, neural apoptosis, and disruption of the circadian regulation of immune responses. Moreover, the development of drugs that target YKL-40, such as humanized anti-YKL-40 antibodies and small molecules, offers promising strategies for blocking AD progression.
Conclusion
This review highlights the potential of YKL-40 as a novel drug target and its implications for enhancing diagnostic precision and treatment strategies in combating Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, Shandong Second Medical University, Weifang, Shandong, China.
- Translational Medical Center, Weifang No.2 People's Hospital, Weifang, Shandong, China.
Förderung
- The Shandong Provincial Natural Science Foundation
- Shandong Provincial Medical and Health Science and Technology Development Program
Zitieren
APA
Sha, Y., Fu, H., Lu, K., Wang, G., & Wang, Y. (2026). The role of YKL-40 in Alzheimer’s disease pathology and drug targeting. PeerJ, 14, e21361. https://doi.org/10.7717/peerj.21361
Vancouver
Sha Y, Fu H, Lu K, Wang G, Wang Y. The role of YKL-40 in Alzheimer’s disease pathology and drug targeting. PeerJ. 2026;14:e21361. doi:10.7717/peerj.21361
BibTeX
@article{Sha2026,
author = {Sha, Yaru and Fu, Hong and Lu, Kun and Wang, Guohui and Wang, Yubing},
title = {The role of YKL-40 in Alzheimer’s disease pathology and drug targeting},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e21361},
doi = {10.7717/peerj.21361}
}
EUVIMED